

Patients First: Navigating Asparaginase-Based Treatment in Young Adults With ALL

Program Overview

Are you up to date on treatment strategies for young adults with acute lymphoblastic leukemia (ALL)? Evolving evidence and clinical guidelines now strongly support the use of asparaginase-based, pediatric-inspired regimens over traditional adult protocols for young adults with ALL. However, many patients continue to be treated with adult protocols that lack asparaginase and are associated with poorer outcomes. In this dynamic, case-based activity, celebrity advocates Rob Benedict and Abbie Cobb, leading leukemia experts, and real people who have been treated for ALL explore practical foundations for successful asparaginase therapy. Leveraging new consensus recommendations, faculty experts explain how to select and when to switch asparaginase formulations, how to monitor serum asparaginase activity, and strategies to mitigate key toxicities while avoiding early asparaginase discontinuation that can compromise survival. Real-world stories from young adults who have been treated for ALL highlight the stakes of getting this right and the challenges of access, adherence, and comprehensive care that clinicians can address in everyday practice.

Learning Goal/Purpose

The goal of this educational activity is to enhance the knowledge, competence, and confidence that hematology/oncology healthcare providers need to achieve better outcomes for young adults with ALL through more consistent application of pediatric-inspired regimens, optimized asparaginase use, and patient-centered care.

Target Audience

Hematologists/oncologists who care for young adults with ALL

Learning Objectives

- Evaluate the latest evidence on the efficacy and safety profiles of pediatric-inspired asparaginase-based ALL treatment protocols for the young adult population
- Employ appropriate monitoring of asparaginase-based protocols in ALL in young adults, including therapeutic drug levels, pharmacokinetics, and clinical values
- Recognize, differentiate, and appropriately manage safety and toxicity issues that can occur during treatment of ALL with asparaginase, such as hypersensitivity reactions, infusion reactions, and other commonly encountered adverse effects

Accredited Provider(s)



In support of improving patient care, this activity has been planned and implemented by Medical Education Resources (MER) and CMEology. MER is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AMA PRA Category 1 Credits™

Physician Credit

Medical Education Resources designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Credit

Medical Education Resources designates this enduring material for a maximum of 1.0 ANCC nursing contact hour.

Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.0 contact hour.

Pharmacy Credit



Medical Education Resources (MER) designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Program Number – JA0003680-9999-25-280-H01-P)

This activity is certified as knowledge-based CPE.

Providership Statement

- This activity is provided by Medical Education Resources (MER) and CMEology.



- This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Disclosure of All Financial Relationships

Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational activities. In accordance with this policy, MER identifies all financial relationships with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Reported financial relationships are mitigated by MER to ensure that all scientific research referred to, reported, or used in a CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing learners with high-quality CE activities that promote improvements or quality in health care and not the business interest of an ineligible company.

The *authors* reported the following financial relationships with ineligible companies whose products or services may be mentioned in this activity:

Dr. Cassaday:

Consultant: Autolus, Pfizer.

Research Funding: Amgen, Kite/Gilead, Incyte, Pfizer, Servier, Vanda Pharmaceuticals.

Honoraria: Amgen, Autolus, Kite/Gilead, Jazz Pharmaceuticals, Inc., Pfizer.

Dr. DeAngelo:

Consultant: Amgen, Autolus, Blueprint, Forty-Seven, Gilead, Incyte, Jazz Pharmaceuticals, Inc., Novartis, Pfizer, Servier, Takeda.

Grants/Research Funding: Abbvie, Blueprint, Glycomimetics, Novartis.

DBMS: Daiichi-Sankyo, Mt. Sinai MPN Consortium.

Accredited Provider Disclosures

<i>Name of Content Manager</i>	<i>Reported Financial Relationship</i>
Planners at Medical Education Resources	No financial relationships to disclose

Planners' and Managers' Disclosures

<i>Name of Content Manager</i>	<i>Reported Financial Relationship</i>
CMEology Planners	No financial relationships to disclose

Disclaimer

The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Medical Education Resources, CMEology, and/or Otsuka America Pharmaceutical, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

INSTRUCTIONS TAB - *Please include any special information the learner should be made aware of, such as, but not limited to: whether the certificate is housed on myCME, how and how often Pharmacy credits are sent to CPE Monitor, and who to contact in the event of an error or problem with the program. Where possible, please include an email address.*

Instructions

In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 70% on the post-assessment. Certificates will be distributed online at the conclusion of the activity.

For information about the accreditation of this program, please contact

<https://cmepartner.org/contact-medical-education-resources/>